Navigation Links
Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product
Date:7/21/2008

SEATTLE, July 21 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has received an R&D contract award from the ONR for approximately $1.6 million to optimize its lead drug candidate for hearing regeneration. SPI has developed a proprietary technology for regenerating auditory sensory cells within the inner ear of mammals involving p27Kip1, a cyclin dependent kinase inhibitor or CKI. CKIs shut down cell division or proliferation in many developing cells and tissues and are often expressed in adult organs to maintain cellular quiescence or terminal differentiation. In the hearing organ of mammals (cochlea), p27Kip1 prevents cellular proliferation and regeneration. For this reason, sensorineural hearing loss is irreversible and often progressive. Once auditory hair cells are lost they are never replaced. In p27 knockout mice, auditory hair cell regeneration occurs due to the unique ability of supporting cells to re-enter the cell cycle, proliferate and regenerate in to supporting cells and replacement hair cells. In p27 wild type mice, this proliferative and regenerative ability is absent. SPI has developed this novel technology into a drug that inhibits p27Kip1 in wild type cells and tissues, and is injecting that drug into the cochlea of deafened Guinea pigs. Results indicate that renewed supporting cell proliferation and hair cell regeneration occur in animals that have lost their hearing due to ototoxic or acoustic injury. In some animals, a return of auditory function has been observed. The ultimate goal of this work is to restore hearing to the severe to profoundly hearing impaired or deaf, especially those with recent traumatic injuries. This novel regenerating strategy may be applied to other non regenerating systems such as the brain or retina where p27Kip1 plays a similar role.

In 2005, the Office of Naval Research began funding this hearing regeneration project. This new funding brings the total level of funding on this specific p27 project to approximately $3 million.

Sound Pharmaceuticals, Inc. is a privately held biopharmaceutical company with a focus on developing the first drugs for hearing loss and brain injury. For more information please contact Jonathan Kil, MD, President and CEO, 206-634-2559 or visit http://www.soundpharma.com.


'/>"/>
SOURCE Sound Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Heel Ultrasound Helps Detect Fracture Risk
2. Accuracy of ultrasound screening in pregnancy: Effects of examiner and device quality unclear
3. Simple ultrasound exam may predict osteoporosis risk
4. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
5. New Heart Ultrasound Research Shows Hope for Diagnosing and Treating Fatal Heart Conditions
6. Siemens New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography
7. Mindrays DC-3 Color Ultrasound Gains U.S. FDA 510(k) Clearance
8. Can SonicMood Help to Significantly Lower High Blood Pressure? The Latest Research Answers With a Resounding YES!
9. World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives
10. ALOKA to Unveil a New Compact ProSound Diagnostic Ultrasound System
11. Journal of Ultrasound In Medicine features bioeffects consensus report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
Breaking Medicine Technology: